Comparative Pharmacology
Head-to-head clinical analysis: MAVIK versus UNIRETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAVIK versus UNIRETIC.
MAVIK vs UNIRETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin-converting enzyme (ACE) inhibitor; inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure and reduced cardiac workload.
Uniretic is a combination of an angiotensin-converting enzyme (ACE) inhibitor (moexipril) and a thiazide diuretic (hydrochlorothiazide). Moexipril inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, increasing excretion of sodium and water.
Oral, 1-4 mg once daily for hypertension; 2-4 mg once daily for heart failure.
1-2 tablets (each containing hydrochlorothiazide 25 mg and spironolactone 25 mg) orally once daily. Maximum dose: 4 tablets/day.
None Documented
None Documented
Trandolaprilat: terminal half-life ~24 hours (range 15–35 hours) for once-daily dosing; effective half-life ~6–10 hours at steady state.
Terminal elimination half-life 13-17 hours; clinical context: supports once-daily dosing
Renal: trandolapril ~33% (as trandolaprilat and metabolites), trandolaprilat ~33% (as unchanged and metabolites); biliary/fecal: ~66% of total radioactivity.
Renal: 50-70% unchanged; biliary/fecal: 10-15% as metabolites
Category C
Category C
ACE Inhibitor
ACE Inhibitor and Diuretic